Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT02303769 Completed - Clinical trials for Benign Prostatic Hyperplasia

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

GL2702
Start date: March 2014
Phase: Phase 3
Study type: Interventional

Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic

NCT ID: NCT02293759 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency

Start date: October 2014
Phase: Phase 4
Study type: Interventional

Patients presented for BPH surgery at our out patient clinic will be assessed for abnormal bleeding profile. Patients with bleeding tendency will be offered either HoLEP or Greenlight laser PVP based on prostate size cut off point of 80ml Larger prostates will be treated with HoLEP Smaller prostates will be treated with greenlight PVP

NCT ID: NCT02283684 Completed - Clinical trials for Benign Prostatic Hyperplasia

GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT

Start date: September 2014
Phase: Phase 4
Study type: Interventional

With a growing body of knowledge on the promising advancements and recent clinical data of the third generations of the Greenlight PVP/XPS, it seems to be a real contender in the world of MIS. Contenders of Greenlight laser technology includes bipolar as well as Holmium laser technology. In this study the investigators planned to test the Greenlight (532-nm) laser PVP using (XPS) 180W system compared to bipolar electro-vaporization, in reduction of LUTS secondary to small to moderate sized BPH in a prospective randomized trial.

NCT ID: NCT02279615 Not yet recruiting - Overactive Bladder Clinical Trials

Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

Start date: December 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of combination therapy involving β3-adrenoceptor agonist, mirabegron, and α-blockers for the treatment of OAB symptoms in male patients with BPH.

NCT ID: NCT02278679 Recruiting - Prostate Cancer Clinical Trials

Digital Rectal Exam Proficiency Tool

DiRECT
Start date: October 2014
Phase: N/A
Study type: Observational

A digital rectal exam proficiency tool, titled the 'DiRECT' was developed based on the consensus of 10 experts. The purpose of this study is to validate this tool for use in both undergraduate and graduate medical education .

NCT ID: NCT02263144 Recruiting - Adenomatous Polyps Clinical Trials

Resect and Discard Extension to FICE of NIcE Classification

FICE;NICE
Start date: May 2014
Phase: N/A
Study type: Observational

The purpose of this prospective, non-interventional study is to validate the Narrow Band Imaging International Colorectal Endoscopic (NICE) classification for differentiating subcentimetric hyperplastic and adenomatous polyps by using Fuji Intelligent Color Enhancement (FICE) technology with high-definition without optical magnification.

NCT ID: NCT02252367 Completed - Clinical trials for Lower Urinary Tract Symptoms

Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms

Start date: December 2015
Phase: Phase 4
Study type: Interventional

At present time several preclinical and clinical study have demonstrated the safety and efficacy of PDE5 (phosphodiesterase type 5)-inhibitors for LUTS/BPH (lower urinary tract symptoms/benign prostatic hyperplasia) patients with or without erectile dysfunction. However, the link between clinical outcomes (symptoms scores), functional activity (urodynamic findings) and molecular pathways, in particular regarding inflammatory pattern (molecular analyses), has not been previously investigated. Aim of present study is to assess, for the first time in literature, changes in pressure flow study (PFS) and changes in molecular profile of prostatic tissue (inflammatory and tissue remodeling markers) in men treated for 12 weeks with tadalafil 5 mg compared with placebo and to correlate these data with changes in symptoms scores (IPSS, International Prostatic Symptoms Score) in men with LUTS secondary to BPH refractory to alpha blockers.

NCT ID: NCT02248467 Completed - Obesity Clinical Trials

Study of the Effect of Testosterone Treatment on Metabolic Parameters and Urinary Symptoms in Bariatric Patients

Start date: May 2013
Phase:
Study type: Observational

The primary purpose of the study is to evaluate, in obese and hypogonadal patients eligible for bariatric surgery, the effect of testosterone replacement therapy in improving lower urinary tract symptoms (LUTS) assessed using the IPSS (International Prostate Symptom Score) questionnaire, compared to hypogonadal untreated subjects and eugonadal subjects.

NCT ID: NCT02245555 Completed - Clinical trials for Prostatic Hyperplasia

Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Start date: April 2006
Phase: N/A
Study type: Observational

Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia

NCT ID: NCT02245542 Completed - Clinical trials for Prostatic Hyperplasia

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Start date: April 2005
Phase: N/A
Study type: Observational

Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia